SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

Super Micro Computer, Inc. engages in the distribution and manufacture of information technology solutions and other computer products. Its products include twin solutions, MP servers, GPU and coprocessor, MicroCloud, AMD solutions, power supplies, SuperServer, storage, motherboards, chassis, super workstations, accessories, SuperRack and server management products. The company was founded by Charles Liang, Yih-Shyan Liaw, Sara Liu, and Chiu-Chu Liu Liang in September 1993 and is headquartered in San Jose, CA.

Super Micro Computer Inc

Super Micros strong quarterly results and raised full-year outlook, driven by AI-server demand, dominate discussion. Bulls view the results as validation and see the shares as undervalued, while skeptics cite margin, cash-flow and credibility concernsand question the muted stock reaction.

Advanced Micro Devices, Inc. engages in the semiconductor business. Its products include processors, accelerators, graphics, adaptive SoCs, FPGAs, and SOMs, and software, tools, and apps. The firm offers artificial intelligence, industries, workloads, and gaming solutions. The company was founded by W. J. Sanders III on May 1, 1969 and is headquartered in Santa Clara, CA.

Advanced Micro Devices Inc.

Advanced Micro Devices Inc

AMDs stronger-than-expected quarterly results and upbeat outlook, driven by surging AI data-center demand, are fueling a sharp rebound and optimism that semiconductor demand remains strong. Bulls are celebrating the growth outlook and squeeze on bearish bets, while skeptics question the valuation, weaker cash flow, and reliance on data-center expansion.

Trump Media & Technology Group Corp. engages in operating social media and in the technology business. Its brands include TRUTH Social, TMTG+, and TMTG News. It operates through the Media and Truth.Fi segments. The Media segment includes products and services such as advertisement through the Truth Social platform. The Truth.Fi segment relates to customized exchange-traded funds or exchange-traded products invested in America First principles, and bitcoin and similar cryptocurrencies or crypto-related securities. The company was founded on March 28, 2024 and is headquartered in Sarasota, FL.

Trump Media & Technology Group Corp.

Midterm election results and the prospect of Democrats gaining control of Congress dominate discussion, with traders debating whether a potential setback for Trump would hurt DJT or ease political risk. Bears expect pressure if Republicans lose ground, while some bulls argue the election may be a routine midterm rebuke and point to the stocks rebound.

Capricor Therapeutics, Inc. is a clinical-stage biotechnology company, which focuses on the development of transformative cell and exosome-based therapeutics for treating Duchenne muscular dystrophy (“DMD”), a rare form of muscular dystrophy which results in muscle degeneration and premature death, and other diseases with unmet medical needs. Its product candidate consists of CAP-1002, Engineered Exosomes, CAP-2003, and Exosome-Based Vaccine. The company was founded on June 17, 1996 and is headquartered in San Diego, CA.

Capricor Therapeutics Inc

A letter from 28 HOPE-3 investigators urging FDA approval of deramiocel has renewed optimism ahead of the agencys Nov. 22 decision for the Duchenne muscular dystrophy therapy. Many traders see the physicians support as strengthening the case for approval and anticipate short covering, while others remain wary of the FDAs prior concerns about the trial data and the binary outcome.

Churchill Capital Corp. XI is a blank check company. It was formed for the purpose of effecting a merger, amalgamation, share exchange, asset acquisition, share purchase, reorganization or similar business combination with one or more businesses. The company was founded by Michael Stuart Klein on June 4, 2025 and is headquartered in New York, NY.

Churchill Capital Corp XI - Ordinary Shares - Class A

Attention centers on Agility Robotics humanoid-robot exposure, with traders comparing it to Unitrees high-profile IPO and citing U.S. restrictions on Chinese robot imports as potential tailwinds. Bulls point to commercial deployments and major backers, while skeptics question the SPAC valuation, limited revenue, and ability to scale.

Arista Networks, Inc. engages in the development, marketing, and sale of cloud networking solutions. Its solutions include EOS, a set of network applications, and Gigabit Ethernet switching and routing platforms. Its product categories include core, cognitive adjacencies, and cognitive networks. The company was founded by Andreas Bechtolsheim, David Cheriton, and Kenneth Duda in November 2004 and is headquartered in Santa Clara, CA.

Arista Networks Inc

Aristas quarterly results beat expectations, and its next-quarter guidance came in well above forecasts, with traders pointing to accelerating AI-networking demand as the key driver. The strong report sparked a sharp rally and bullish calls for further gains, though some caution that elevated valuation and volatile post-earnings trading could bring profit-taking.

Duolingo, Inc. is a language-learning website and mobile application, which engages in the development of a free language learning website and crowd sourced text translation platform. It offers Duolingo for Schools, a free, web-based tool that aims to make it easier for teachers to use the Duolingo platform in a structured learning environment, and English Test, an online, on-demand assessment of English proficiency. The company was founded by Luis von Ahn and Severin Hacker in 2011 and is headquartered in Pittsburgh, PA.

Duolingo Inc - Ordinary Shares - Class A

Duolingo Inc

Duolingos Q3 results and raised full-year guidance are driving discussion: traders point to accelerating user growth and revenue and bookings above expectations, while noting a slight EPS miss. Reactions are split, with optimism that AI can improve the product countered by concerns about monetization, valuation and the shares post-earnings pullback.

Astera Labs, Inc. provides rack-scale AI infrastructure through purpose-built connectivity solutions. The company offers a range of semiconductor-based connectivity solutions designed to address bandwidth, latency, and reliability challenges in AI and cloud data centers. The company was founded by Jitendra Mohan, Casey Morrison, and Sanjay Gajendra in October 2017 and headquartered in San Jose, CA.

Astera Labs Inc.

Astera Labs Inc

Astera Labs strong quarterly results and raised outlook are drawing attention, but shares sold off despite the beat. Traders are debating whether the reaction reflects lofty valuation and concerns about AI-data-center spending or a buying opportunity, with dip-buyers pointing to continued growth in connectivity products.

Block, Inc. engages in creating ecosystems for distinct customer audiences. It operates through the following segments: Square and Cash App. The Square segment provides payment services, software solutions, hardware, and financial services to sellers. The Cash App segment includes the financial tools available to individuals within the mobile Cash App, including peer-to-peer payments, bitcoin and stock investments. The company was founded by Jack Patrick Dorsey and James Morgan McKelvey in February 2009 and is headquartered in Oakland, CA.

Block Inc - Ordinary Shares - Class A

Block Inc

Blocks Q3 earnings beat estimates and the company raised its 2026 profit outlook, drawing bullish calls on growth in Cash App and Square. Skeptics question the quality of the beat, pointing to Bitcoin-related gains, rising credit losses and expenses, while some traders say the shares have failed to sustain the positive reaction.

Ouster, Inc. engages in the provision of high resolution digital lidar sensors that offer advanced 3D vision to machinery, vehicles, robots, and fixed infrastructure assets. The company was founded by Angus Pacala and Mark Frichtl on June 30, 2015 and is headquartered in San Francisco, CA.

Ouster Inc - Ordinary Shares - Class A

Ousters Q3 results and revenue outlook are driving attention, with traders focusing on growth and the planned Rev8 lidar production ramp for robotics and other Physical AI uses. Reactions are broadly positive on the reported beat, but some traders question the outlook and flag weaker gross margins as a risk.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Dogecoin

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

ADC Therapeutics to Present at November Investor Conferences

ADC Therapeutics to Present at November Investor Conferences ADC Therapeutics to Present at November Investor ConferencesPR NewswireLAUSANNE, Switzerland, Nov. 3, 2026 LAUSANNE, Switzerland, Nov. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer...

ADC Therapeutics Announces New Employee Inducement Grant

ADC Therapeutics Announces New Employee Inducement Grant ADC Therapeutics Announces New Employee Inducement GrantPR NewswireLAUSANNE, Switzerland, Nov. 2, 2026 LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT), a commercial-stage global leader and pioneer in the...

ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026

ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026 ADC Therapeutics to Announce Third Quarter 2026 Financial Results on November 9, 2026PR NewswireLAUSANNE, Switzerland, Nov. 2, 2026 LAUSANNE, Switzerland, Nov. 2, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE...

ADC Therapeutics Announces ZYNLONTA Updates in Japan

ADC Therapeutics Announces ZYNLONTA Updates in Japan ADC Therapeutics Announces ZYNLONTA Updates in JapanPR NewswireLAUSANNE, Switzerland, Oct. 29, 2026 Licensing partner, Tanabe Pharma, filed for Japanese approval of ZYNLONTA (MT-2111) for relapsed or refractory DLBCL based on encouraging Japanese...

NeoGenomics (NEO) Q3 Earnings and Revenues Beat Estimates

NeoGenomics (NEO) delivered earnings and revenue surprises of +16.67% and +0.66%, respectively, for the quarter ended September 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements

ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure Improvements ADC Therapeutics Announces Comprehensive Strategic Financial Restructuring Marking Key Capital Structure ImprovementsPR NewswireLAUSANNE, Switzerland, Oct. 8, 2026$86.6 Million...

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference

ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference ADC Therapeutics to Participate in the 2026 Cantor Global Healthcare Conference PR Newswire LAUSANNE, Switzerland, Sept. 3, 2026 LAUSANNE, Switzerland, Sept. 3, 2026 /PRNewswire/ -- ADC Therapeutics SA (NYSE: ADCT...

ADC Therapeutics (ADCT) Q2 2026 Earnings Call Transcript

@media (max-width: 768px) {
 .image-container {
 width: 100% !important;
 float: none !important;
 margin: 0 0 1rem 0 !important;
 }
 }

Image source: The Mo...

ADC Therapeutics Q2 2026 Earnings Call Transcript

On Thursday, ADC Therapeutics (NYSE:ADCT) discussed second-quarter financial results during its earnings call. The full transcript is provided below.
This content is powered by Benzinga APIs. For comprehensive financialread more...

ADC Therapeutics SA (ADCT) Reports Q2 Loss, Lags Revenue Estimates

ADC Therapeutics (ADCT) delivered earnings and revenue surprises of +42.11% and -4.48%, respectively, for the quarter ended June 2026. Do the numbers hold clues to what lies ahead for the stock?

ADC Therapeutics SA is a clinical-stage biotechnology company, which engages in the research and development and commercialization of targeted antibody drug conjugates for patients with hematological malignancies and solid tumors. Its clinical-stage product candidates include loncastuximab tesirine, camidanlumab tesirine, and ADCT-602. The company was founded by Christopher Martin on June 6, 2011 and is headquartered in Epalinges, Switzerland.

Adc Therapeutics SA

ADC Therapeutics To Cut About 17% Of Its Staff – A Look At Some Key Details

Equity

Bearish Sentiment

<ul class="summary-bullets"><li>ADC Therapeutics said that the reduction in workforce is driven by the expected completion of LOTIS-5 and LOTIS-7 trials.</li><li>The company expects to deliver on its key clinical, regulatory, and manufacturing activities while managing commercial activities to aid ZYNLONTA.</li><li>The company is now preparing for a scheduled pre-supplemental Biologics License Application (pre-sBLA) with the FDA in August 2026.&nbsp;</li></ul>ADC Therapeutics (ADCT) on Wednesday announced it would cut its global workforce by about 17% to focus on its ZYNLONTA franchise and regulatory and clinical milestones.At the time of writing, ADCT stock was down 2.6% during Wednesday’s premarket session.ADC Therapeutics said the reduction in workforce is driven by the expected completion of the LOTIS-5 and LOTIS-7 trials, both evaluating its targeted cancer therapy ZYNLONTA this year, and operational efficiencies.&nbsp;<h2 class="st-heading-2">ADCT Aims To Increase Financial Flexibility</h2>With these changes, the company expects to deliver on its&nbsp;key clinical, regulatory, and manufacturing activities, while managing commercial activities to aid ZYNLONTA,&nbsp;ADC Therapeutics noted."This strategic reorganization will enable us to increase our financial flexibility as we prepare for upcoming LOTIS-5 regulatory milestones and continue building on the broader opportunity for ZYNLONTA through LOTIS-7 and support for the indolent lymphoma investigator-initiated trials (IITs),” said Ameet Mallik, Chief Executive Officer at ADC Therapeutics.The firm expects to generate annualized cost savings of about $10 million and incur one-time pre-tax charges of about $3 million. The majority of these costs will be recognized in the second quarter of 2026, according to the company.&nbsp;ADC Therapeutics expects its cash runway to extend at least through 2028.<h2 class="st-heading-2">ADCT’s Regulatory Pipeline</h2>The company is now preparing for a scheduled pre-supplemental Biologics License Application (pre-sBLA) with the Food and Drug Administration (FDA) in August 2026.&nbsp;ADC Therapeutics aims to discuss a possible regulatory way forward for ZYNLONTA in combination with rituximab to treat relapsed or refractory diffuse large B-cell lymphoma (r/r DLBCL), a type of blood cancer that has returned or hasn’t responded to previous therapy, following the topline data from the Phase 3 LOTIS-5 trial.<h2 class="st-heading-2">What Retail Thinks Of ADCT</h2>On Stocktwits, retail sentiment surrounding the stock has remained ‘bearish’ amid ‘low’ message volumes in the past 24 hours.One user on Stocktwits said that the reorganization shows the company’s commitment to disciplined spending. <stembedurl>https://stocktwits.com/Spartrap/message/657285140</stembedurl>ADCT stock has declined by more than 67% so far this year.For updates and corrections, email newsroom[at]stocktwits[dot]com.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/why-is-fcel-stock-surging-today-june-24-2026/cZKyBvGR7fX">Why Is FCEL Stock Surging Today?</a>

In this photo illustration, the ADC Therapeutics logo is displayed on the screen of the tablet. (Photo Illustration by Sheldon Cooper/SOPA Images/LightRocket via Getty Images)

ADC Therapeutics expects to generate annualized cost savings of about $10 million and incur one-time pre-tax charges of about $3 million.

Current Price	$1.55
Prev Close	$1.54
Open	$1.58
Dividend Yield	0.00%
50-Day Moving Average	$1.32
Beta	1.68
Avg. Volume	1.56M
PE Ratio	-2.32

52-Week High	$4.98
52-Week Low	$0.7796
Market Capitalization	$196.61M
EPS (Annual)	-$1.12
Price to Book	-0.86
Revenue Per Employee	$421,538.86

Feed

News

Sentiment

Earnings

Fundamentals

Info

ADCT Fundamentals